Literature DB >> 27474733

[Immune-mediated neuropathies].

G Stoll1, K Reiners2.   

Abstract

The Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are the most common immune-mediated polyneuropathies, which can show variable clinical and electrophysiological manifestations. Rarer immune-mediated neuropathies encompass paraproteinemic neuropathies (PPN), multifocal motor neuropathy (MMN) and vasculitic neuropathies. The diagnosis usually relies on the history of symptom evolution, distribution of nerve dysfunction and particularly on characteristic features in nerve conduction studies, aided by cerebrospinal fluid (CSF) examination and nerve biopsy findings. The therapeutic toolbox encompasses corticosteroids, immunoglobulins and plasmapheresis often accompanied by long-term immunosuppression. It is important to note that immune-mediated neuropathies selectively respond to treatment and contraindications need to be considered. Despite treatment a considerable number of patients suffer from permanent neurological deficits.

Entities:  

Keywords:  Chronic inflammatory demyelinating polyneuropathy; Guillain-Barré syndrome; Immunosuppression; Mononeuritis multiplex; Multifocal motor neuropathy

Mesh:

Substances:

Year:  2016        PMID: 27474733     DOI: 10.1007/s00115-016-0164-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  29 in total

1.  Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary.

Authors:  Michael P Collins; P James B Dyck; Gary S Gronseth; Loïc Guillevin; Robert D M Hadden; Dieter Heuss; Jean-Marc Léger; N C Notermans; John D Pollard; Gérard Said; Gen Sobue; A F J E Vrancken; John T Kissel
Journal:  J Peripher Nerv Syst       Date:  2010-09       Impact factor: 3.494

2.  European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.

Authors:  R D M Hadden; E Nobile-Orazio; C Sommer; A Hahn; I Illa; E Morra; J Pollard; R A C Hughes; P Bouche; D Cornblath; E Evers; C L Koski; J M Léger; P Van den Bergh; P van Doorn; I N van Schaik
Journal:  Eur J Neurol       Date:  2006-08       Impact factor: 6.089

Review 3.  Vasculitic neuropathies.

Authors:  Kelly Graham Gwathmey; Ted Michael Burns; Michael Paul Collins; P James Bonham Dyck
Journal:  Lancet Neurol       Date:  2014-01       Impact factor: 44.182

4.  Ten steps in characterizing and diagnosing patients with peripheral neuropathy.

Authors:  P J Dyck; P J Dyck; I A Grant; R D Fealey
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

Review 5.  Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy.

Authors:  Roy Freeman
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

Review 6.  Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome).

Authors:  Nobuhiro Yuki
Journal:  J Neuroimmunol       Date:  2009-07-29       Impact factor: 3.478

Review 7.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

Review 8.  Imaging of the peripheral nervous system.

Authors:  Guido Stoll; Einar Wilder-Smith; Martin Bendszus
Journal:  Handb Clin Neurol       Date:  2013

9.  Mortality in Guillain-Barre syndrome.

Authors:  Bianca van den Berg; Carina Bunschoten; Pieter A van Doorn; Bart C Jacobs
Journal:  Neurology       Date:  2013-04-10       Impact factor: 9.910

Review 10.  Autoantibodies in systemic vasculitis.

Authors:  Alexandre Wagner Silva de Souza
Journal:  Front Immunol       Date:  2015-04-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.